NeuroDerm (NDRM) Misses Q2 EPS by 12c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/20/2026
- Wall St indexes fall to two-week lows as rising bond yields, disappointing Walmart results drag
- Walmart shares fall despite earnings beat
- Alibaba stock dips as Q2 profit misses estimates despite strong AI cloud growth
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Moderna stock pulls back after massive one-day rally: analysts weigh in
- Marvell issues Google warrant tied to custom chip deal
- FOMC minutes from July 28-29th meeting
- US stock futures steady after tech slump; investors focus on Middle East tensions
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Deutsche Bank calls Treasury buyback doubling similar to ’operation twist’
NeuroDerm Announces Second Quarter 2016 Financial Results and Provides Corporate Update
August 25, 2016 7:25 AM EDTREHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (NASDAQ: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) diseases, today announced financial results for the second quarter ended June 30, 2016 and provided a corporate update.
We have been very productive in recent months advancing our clinical programs and moving closer toward our goal of providing a less invasive, continuous levodopa delivery treatment option for patients suffering from Parkinsons disease, said Oded Lieberman, PhD, CEO of NeuroDerm. We announced that Trial 005, evaluating ND0612H to DUODOPA® in a head-to-head... More
NeuroDerm Initiates Patient Enrollment in a Phase III Trial of ND0612L for the Treatment of Parkinson’s Disease
August 25, 2016 7:18 AM EDTREHOVOT, Israel, Aug. 25, 2016 (GLOBE NEWSWIRE) -- NeuroDerm Ltd. (Nasdaq: NDRM), a clinical stage pharmaceutical company developing drugs for central nervous system (CNS) disorders, today announced that it has initiated enrollment of Parkinson's disease (PD) patients in a Phase III efficacy trial (trial 007, named the "iNDiGO" trial) of ND0612L, the companys low-dose continuous, subcutaneously delivered levodopa/carbidopa (LD/CD) liquid formulation.
iNDiGO is a 16-week, international, multicenter, randomized, double-blind, placebo controlled, parallel group study designed to compare the efficacy, safety and tolerability of continuous subcutaneous infusion of... More
